Thyrotropin-releasing hormone and its analog MK-771 increase the cerebroventricular perfusate content of dihydroxyphenylacetic acid

Systemic administration of thyrotropin-releasing hormone enhances striatal dopamine release in vivo

We examined the effects of systemically administered thyrotropin-releasing hormone (TRH) on the release of dopamine (DA), as assessed by brain microdialysis within the corpus striatum of anesthetized rats. A single dose (10 micrograms i.v.) elevated DA levels in brain extracellular fluid (ECF) by 240% above baseline levels after 150 min. Systemic tyrosine ([TME] 20 mg/kg i.v.) also increased DA release (by 190% after 150 min), while combined treatment with both agents was associated with significant potentiation of the DA response (to 640% after 150 min). None of the treatments significantly altered striatal tissue levels of DA or its metabolites. A large dose of TRH (50 micrograms i.v.) significantly increased DA release (by 1150%) whether or not animals had received an active or denatured prolactin (PRL) antiserum prior to the experiment, suggesting that the TRH effect is not mediated by PRL. Although TRH is rapidly metabolized in plasma and penetrates the blood-brain barrier only poorly, our results suggest that even relatively small doses of the hormone can affect striatal dopaminergic neurotransmission.

Neuropeptide-dopamine interactions. IV. Effect of thyrotropin-releasing hormone on striatal dopaminergic neurons

Many biologic effects of TRH seem to be mediated via a dopaminergic mechanism. The present study examined the effects of chronic TRH administration on the properties of nigrostriatal dopaminergic neurons. Ten days, continuous subcutaneous TRH administration via an osmotic minipump led to a significant rise in striatal level of 3,4-dihydroxyphenylacetic acid, but not of homovanillic acid or dopamine. These treatments also did not elicit any significant changes in the maximal binding capacity (Bmax) or affinity (KD) of either D1- or D2-dopamine receptor. By contrast, TRH administration led to a significant increase in both Bmax and KD of striatal mazindol binding. This effect of TRH, however, was not observed in in vitro studies. In conclusion, these data suggest that in vivo administration of TRH may modulate dopaminergic activities by altering, directly or indirectly, dopamine release and reuptake.

Modulation of dopamine receptors by thyrotropin-releasing hormone in the rat brain

Nanomolar concentration of thyrotropin-releasing hormone (TRH) in vitro caused a significant reduction of [3H]apomorphine binding sites (70% of the control) in the rat striatum and the limbic forebrain. [3H]Spiperone binding was not affected by TRH. On the other hand, dopamine and apomorphine displaced [3H]TRH binding partially, suggesting the presence of a TRH receptor subpopulation that has a high affinity for dopamine agonist. Most of the neuroleptics displaced [3H]TRH binding dose-dependently in the micromolar range. (-)-Sulpiride had no affinity to TRH receptors. These findings suggest that one of the important roles of TRH as a neuromodulator is to modulate receptors for classical neurotransmitters, and this receptor-receptor interaction may be of importance in explaining the well known stimulating effects of TRH on the dopaminergic system.

Effect of TRH analog (DN-1417) on tyrosine hydroxylase activity in mesocortical, mesolimbic and nigrostriatal dopaminergic neurons of rat brain

Tyrosine hydroxylase (TH) was assayed in eight regions of rat brain following repeated treatment with a TRH analog, DN-1417 (gamma-butyrolactone-gamma-carbonyl-histidyl-prolinamide). Repeated DN-1417 treatment (20 mg/kg/day, IP) for 7 days increased TH activity in the ventral tegmental area and decreased in the prefrontal cortex polar, medial and lateral fields and olfactory tubercles. No significant change in TH activity was found in the nucleus accumbens, striatum and substantia nigra. Kinetic analysis showed that the increased TH activity in the ventral tegmental area was due to an increase in Vmax, but not a change in the apparent Km of TH for a cofactor, 6-methyl-tetrahydropteridine. When TH was assayed at a suboptimal pH and in the presence of a subsaturating cofactor, the striatal TH was activated significantly after DN-1417. In the prefrontal cortex medial field, nucleus accumbens and olfactory tubercles, TH activity assayed under the suboptimal condition was not modified by DN-1417 treatment. These results suggest an intimate involvement of central dopaminergic systems in the actions of DN-1417.

Interaction between thyrotropin-releasing hormone and the mesolimbic dopamine system

The involvement of the mesolimbic dopamine (DA) system in the excitatory behavioral effects of thyrotropin-releasing hormone (TRH) has been a controversial topic. In this study TRH was injected into the nucleus accumbens, lateral ventricles or ventral tegmental area and changes in spontaneous motor activity and metabolism of DA in the nucleus accumbens and striatum measured. Injection of TRH into all three areas of the brain produced an increase in photocell counts of locomotor activity and, in the nucleus accumbens, a significant decrease in photocell counts of rearing was measured. Injection of TRH into the nucleus accumbens caused a marked increase in metabolism of DA in both the nucleus accumbens and striatum. A smaller increase in metabolism of DA was also observed after injection of TRH into the lateral ventricles, but no significant change was found after intra-ventral tegmental administration of TRH. These data indicate that while TRH probably acts in the nucleus accumbens to enhance the metabolism of DA, and presumably release of DA, the excitatory behavioral effect of TRH is only partially mediated by this dopaminergic mechanism.

Effect of DN-1417, a thyrotropin releasing hormone analog, on dopaminergic neurons in rat brain

Acute and chronic effects of gamma-butyrolactone-gamma-carbonyl-histidyl-prolinamide (DN-1417) were investigated on motor activity, dopamine (DA) metabolites and DA receptors in various brain regions of rats. The motor activity, as measured with Automex recorder, was enhanced after a single injection with DN-1417 (20 mg/kg, IP), and the motor stimulating action persisted during 21 daily injections. Acute DN-1417 elevated both homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in 7 brain regions, prefrontal cortex polar, medial and lateral fields, nucleus accumbens, olfactory tubercles, amygdala and striatum. After chronic treatment for 7 days, the acute effect of DN-1417 on DA metabolites disappeared in all regions except for the striatum in which DN-1417 still increased HVA and DOPAC. The response of striatal DA metabolites was also observed after chronic treatment for 21 days. Chronic DN-1417 produced no significant change in 3H-spiperone binding in the prefrontal cortex, nucleus accumbens, olfactory tubercles and striatum, while striatal 3H-DA binding displaced by 30 nM spiperone was enhanced after chronic treatment. These results indicate that DN-1417 interacts with mesocortical, mesolimbic and nigrostriatal DA systems in the different modes of action. The lack of tolerance to motor hyperactivity, however, raises the question as to whether DN-1417-induced hyperactivity may be mediated by the activation of mesolimbic DA neurons. The involvement of nigrostriatal neurons in DN-1417-induced motor hyperactivity is suggested.

Effects of TRH, ethanol, and TRH-ethanol combination on activity in rats with altered monoamine content

Investigations were undertaken with 5,7-dihydroxytryptamine and 6-hydroxydopamine treated rats to see whether activity changes induced by TRH, ethanol and the TRH-ethanol combination would be affected after reduced monoamine function. In keeping with earlier results, TRH increased activity, ethanol reduced activity and the TRH-ethanol combination produced activity counts greater than those for TRH alone. Neither the 5,7-dihydroxytryptamine-induced reduction of brain serotonin nor the 6-hydroxydopamine treatments which reduced brain catecholamines altered the hyperactivity induced by TRH or the TRH-ethanol combination. While reduction of brain serotonin did not affect the ethanol-induced changes in activity, preferential reduction of dopamine as well as reduction of both norepinephrine and dopamine significantly antagonized this measure of ethanol-induced depression. The reduction of dopamine alone produced the greatest effect on this action of ethanol. It can be concluded from the data that the increased locomotion induced by TRH and the TRH-ethanol combination does not depend upon endogenous monoamines, whereas the sedative effects of ethanol are apparently influenced by alterations in brain catecholamine function.